Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lymphdiaral Basistropfen is a homeopathic oral solution developed and marketed by PASCOE pharmazeutische Präparate GmbH. It is a multi-ingredient combination product composed of several botanical and mineral constituents, including Taraxacum, Calendula, Arsenicum album, Chelidonium, Echinacea, Phytolacca, Hydrastis, Lycopodium, and Sanguinaria, in an ethanol-based solution. Traditionally used in homeopathic medicine, its primary indication is the adjuvant treatment of infections of the upper respiratory system, particularly those involving the local lymphatic system. The drug has also been investigated in clinical research for the treatment of chronic low-back pain. As a homeopathic preparation, it is intended to support the body's self-regulatory and lymphatic processes rather than targeting a specific molecular biological pathway in the conventional pharmacological sense.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lymphdiaral Basistropfen (Pascoe Naturmedizin).